Loading clinical trials...
Loading clinical trials...
Celsior® is an organ preservation solution used for the harvesting and the preservation of solid organs. Its use as a crystalloid cardioplegia solution has been established recently. Its main advantage is the long duration of myocardial protection. Compared to the other cardioplegia solutions, it allows a reduced amount of solution administered during the surgery and fewer interruptions during the intervention for the administration of supplemental doses of cardioplegia for long and complex operations. The objective of this register is to compare the safety and the efficacy of Celsior® to the old cardioplegia solution Saint-Thomas used as cardioplegia solution in surgery of the transposition of great vessels, the arterial switch operation.
Age
All ages
Sex
ALL
Healthy Volunteers
No
: Hôpital Louis Pradel - Service de Chirurgie Cardiaque C
Bron, France
Start Date
September 1, 2020
Primary Completion Date
December 1, 2020
Completion Date
December 1, 2020
Last Updated
November 6, 2020
200
ESTIMATED participants
CELSIOR® group
DRUG
Saint-Thomas group
DRUG
Lead Sponsor
Hospices Civils de Lyon
NCT05809310
NCT03049540
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions